NCT04928365 is a Phase 2 clinical trial of Anti-PD-1 monoclonal antibody in Melanoma, sponsored by Blokhin's Russian Cancer Research Center.

Who is sponsoring NCT04928365?

NCT04928365 is sponsored by Blokhin's Russian Cancer Research Center.

What drugs are being tested in NCT04928365?

Interventions in NCT04928365: Anti-PD-1 monoclonal antibody.

Is NCT04928365 still recruiting?

NCT04928365 is currently status unknown. Last updated 16 June 2021.

Last reviewed 2021-06-16 · How we verify

NCT04928365

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Status unknown Phase 2 Last updated 16 June 2021

What this trial tests

Phase 2 trial testing Anti-PD-1 monoclonal antibody in Melanoma in 50 participants. Status unknown.

Timeline

25 March 2021

Primary endpoint
11 May 2021

25 March 2023

Quick facts

Lead sponsor	Blokhin's Russian Cancer Research Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	25 March 2021
Primary completion	11 May 2021
Estimated completion	25 March 2023
Sites	1 location across Russia

Drugs / interventions tested

Anti-PD-1 monoclonal antibody — full drug profile →

Conditions studied

Melanoma — all drugs for Melanoma →

Sponsor

Blokhin's Russian Cancer Research Center — full company profile →

Who can join

18 and older, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open prospective clinical trial to develop the computer software (Intelligent prognostic system) for predicting the efficacy of anti-PD-1 immunotherapy of melanoma patients in routine practice

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.
Adams R, Moser B, Karagiannis SN, Lacy KE. · · 2021 · cited 10× · PMID 34830780 · DOI 10.3390/cancers13225625

Verify or expand the search:

Other trials of Anti-PD-1 monoclonal antibody

Trials testing the same drug.

NCT07365592 — Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC · Phase 1, PHASE2 · not yet recruiting
NCT06603844 — First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. · Phase 1, PHASE2 · recruiting
NCT06556199 — A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar · Phase 1, PHASE2 · recruiting
NCT06728657 — Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma · Phase 2 · suspended
NCT06349044 — A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed · NA · recruiting

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Blokhin's Russian Cancer Research Center trials

Trials by the same sponsor.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07448662 — Local Treatment Strategies for Brain Metastases of Colorectal Cancer · active not recruiting
NCT06967155 — A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metasta · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04928365 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Blokhin's Russian Cancer Research Center
Last refreshed: 16 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04928365.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing